Business Wire

Der hier verfügbare Newsfeed wird von unserem Content-Partner Business Wire bereitgestellt. Es handelt sich dabei um einen der bedeutendsten und reichweitenstärksten Pressedienste, die Nachrichten, Pressemitteilungen und Multimedia-Inhalte an Medien, Journalisten und der Öffentlichkeit zur Verfügung stellen. Business Wire ist ein Tochterunternehmen des Warren-Buffett-Konzerns Berkshire Hathaway.
Der NewsWire-Hub ("X-Billboard") umfasst derzeit vfünf der wichtigsten internationalen Nachrichtenquellen und wird durch einen Börseninformationsservice ergänzt. Die einzelnen Newswire-Services ergänzen sich und bilden ein komplementäres Informationsangebot, mehr als drei Viertel der offiziellen Nachrichtenquellen ab, auf die sich Redaktionen weltweit bei ihrer Börsenberichterstattung stützen. Ihr Vorteil: Sie finden hier alles in einer Übersicht. Über die Steuerelemente können Sie zu den einzelnen Bereichen navigieren. Im Terminalview können Sie gezielt auf Unternehmensebene individuelle Recherchen durchführen.
presented by
H
More Tools & Gadgets
F&G: 64
6.449,93 S&P · 15,83 Vola-Index · 118.182,31 BTC · 1,17041 EURUSD
Systemstatus: 55.139 Nachrichten wurden bislang erfolgreich verarbeitet
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
US77313F1066
Letzte Aktualisierung: 17.08.2025 | 3PM
Kennen Sie bereits den neuen Terminal-View? Folgen Sie bei Interesse dem folgenden Link.
FIGI: BBG000WG3567
RCKT
Rocket Pharmaceuticals Inc
GICS: - · Sektor: EQTY · Sub-Sektor: Biotechnology
NAME
Rocket Pharmaceuticals Inc
ISIN
US77313F1066
TICKER
RCKT
MIC
XNAS
REUTERS
RCKT.OQ
BLOOMBERG
RCKT US
Sa., 02.08.2025       Rocket Pharmaceuticals
US77313F1066

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025. Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Do., 24.07.2025       Rocket Pharmaceuticals
US77313F1066

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strategic corporate reorganization and pipeline prioritization aimed at maximizing near-term value, extending operational runway into the ...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Do., 17.07.2025       Rocket Pharmaceuticals
US77313F1066

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A601, the Compa...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Silent Ad
Mo., 30.06.2025       Rocket Pharmaceuticals
US77313F1066

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Fr., 27.06.2025       Rocket Pharmaceuticals
US77313F1066

Glancy Prongay & Murray LLP reminds investors of the upcoming August 11, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Do., 26.06.2025       Rocket Pharmaceuticals
US77313F1066

Law Offices of Howard G. Smith reminds investors of the upcoming August 11, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”). IF YOU ARE ...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Di., 24.06.2025       Rocket Pharmaceuticals
US77313F1066

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (t...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Mo., 23.06.2025       Rocket Pharmaceuticals
US77313F1066

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”). Rocket investors have until August 11, 2025 to file a lead plaintif...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Mo., 23.06.2025       Rocket Pharmaceuticals
US77313F1066

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”). Rocket investors have until August 11, 2025 to file a lead plaintiff ...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Fr., 20.06.2025       Rocket Pharmaceuticals
US77313F1066

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY O...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Silent Ad
Fr., 20.06.2025       Rocket Pharmaceuticals
US77313F1066

Law Offices of Howard G. Smith announces an investigation on behalf of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ROCKET PHARMACEUTICALS, INC. (RCKT), CONTACT THE LAW OFFICES OF HOWARD G. S...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Do., 19.06.2025       Rocket Pharmaceuticals
US77313F1066

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captio...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Do., 19.06.2025       Rocket Pharmaceuticals
US77313F1066

The Law Offices of Frank R. Cruz announces an investigation of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ROCKET PHARMACEUTICALS, INC. (RCKT), CLICK HERE TO INQUIRE ABOUT POTENTIALL...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Sa., 14.06.2025       Rocket Pharmaceuticals
US77313F1066

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action laws...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Fr., 13.06.2025       Rocket Pharmaceuticals
US77313F1066

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. ...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Do., 12.06.2025       Rocket Pharmaceuticals
US77313F1066

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”). Rocket Pharmaceuticals is a fully integrated, late-stage ...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Di., 27.05.2025       Rocket Pharmaceuticals
US77313F1066

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to RP-A501, its investigational gene therapy for Danon disease. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Do., 15.05.2025       Rocket Pharmaceuticals
US77313F1066

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced preliminary data from the Phase 1 clinical trial of RP-A601 for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-A...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Fr., 09.05.2025       Rocket Pharmaceuticals
US77313F1066

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the company will be presenting data for the first time from the Phase 1 clinical trial of RP-A601 to treat patients with plakophilin-2 ...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Do., 08.05.2025       Rocket Pharmaceuticals
US77313F1066

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the first quarter ending March 31, 2025. "Rocket maintained strong momentum during the first qu...
weiterlesen
Rocket Pharmaceuticals
Research & Analysen Termsheet Terminal
Permalink
Silent Ad

Die hier zur Verfügung gestellten Informationen unterliegen keiner redaktionellen Bearbeitung. Die Aufbereitung erfolgt vollautomatisch und wird durch Zusatzinformationen und weiterführende Recherchemöglichkeiten angereichert. Ziel der Inhalte ist die schnelle und unkomplizierte Versorgung der Informationssuchenden mit den für sie relevanten Informationen. Durch eine Rückverlinkung auf den Informationsanbieter und -eigentümer ist sichergestellt, dass die hier aufbereiteten Daten bei Bedarf mit den Quellinformationen abgeglichen werden können. Das Newsboard zeigt keine Informationen in Echtzeit. Diese bitten wir bei Bedarf beim Börsenbetreiber abzurufen. Es besteht kein Anspruch auf Vollständigkeit. Hochverfügbarkeit kann nicht gewährleistet werden. Sollten Sie Fehler in der Funktionsweise bemerken, teilen Sie uns diese über das weiter unten befindliche Formular "Report a Bug" mit.

RAW DATA PROCESSING bedeutet, dass Rohdaten verarbeitet werden, ohne den Inhalt zu verändern. Um die Interpretation der Information im Sinne der Nutzbarkeit zu verbessern, werden die Daten ergänzt. 

Hinweis: Über das Newswire-Crosslink-Panel im oberen Bereich gelangen Sie schnell und bequem zu weiteren Informationsquellen. Im Terminalview sind die Nachrichten auf Unternehmensebene gefiltert und ermöglich darüber gezielte Recherchen.

Wir bedanken uns im Namen der Investoren-Community bei BusinessWire für die Bereitstellung der News- und Datenfeeds

 

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S